AI brief of an SEC Form 8-K · Blaize Holdings, Inc. (BZAI)

Blaize Reports Preliminary Q3 Revenue of $0.5 Million and Revises 2026 Revenue Guidance

Negative Impact 4 of 5 guidance Written later

Blaize Holdings said preliminary third-quarter 2026 revenue is about $0.5 million, earned from one European hardware customer in August, and revised full-year 2026 revenue guidance to $32.0 million to $36.0 million. The filing also discloses a DOJ investigation and SEC inquiry, a class action filed September 17, 2026, and an agreed extension of a $13.3 million NeoTensr receivable, which shareholders should weigh alongside the revenue outlook.

Key points

  • Preliminary Q3 2026 revenue of approximately $0.5 million, subject to quarter-end closing procedures that are not complete.
  • Full-year 2026 revenue guidance revised to $32.0 million to $36.0 million; the filing does not state the prior guidance range.
  • NeoTensr paid $0.2 million on September 30, 2026 toward a $13.3 million receivable that was due September 24, 2026; payment terms were extended to the fourth quarter of 2026.
  • DOJ subpoenas and SEC inquiries received in July and August 2026; a class action was filed September 17, 2026 in the U.S. District Court for the Central District of California.

The filing

CompanyBlaize Holdings, Inc. (BZAI)
Form8-K, current report
Filed with the SECOct 5, 2026, 8:32 PM ET
Accession number0001871638-26-000063

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.